Daniel P. Petrylak, MD, presented “Novel Targeted Therapies” during the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Petrylak, Daniel P. “Novel Targeted Therapies.” October 8, 2024. Accessed Feb 2025. https://grandroundsinurology.com/novel-targeted-therapies/
Novel Targeted Therapies – Summary
Daniel P. Petrylak, MD, presents a detailed 9-minute discussion on novel targeted therapies for prostate cancer. The discussion focuses on the challenges and advances in addressing androgen receptor (AR) mutations and resistance mechanisms in castration-resistant prostate cancer (CRPC). The AR’s central role in disease progression is underscored, and resistance pathways are addressed.
Dr. Petrylak introduces PROTAC (proteolysis-targeting chimera) technology as a promising solution for targeting AR resistance. Early clinical trials of PROTAC ARV-110 demonstrated its effectiveness. The development of ARV-766, a next-generation PROTAC, broadens the therapeutic scope by targeting additional AR mutations and showing improved outcomes in preliminary trials. ARV-766 is now progressing to phase III trials, representing a promising step forward in personalized prostate cancer treatment.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Daniel P. Petrylak, MD, leads the genitourinary cancers medical oncology team at Smilow Cancer Hospital as director of the genitourinary cancer research group, professor, and co-director of the Cancer Signaling Network program. Dr. Petrylak joined Yale from Herbert Irving Cancer Center at Columbia University Medical Center with New York-Presbyterian Hospital, where he served as Professor of Medicine (Medical Oncology) and Urology and began his appointment in September of 2012. After serving for more than 20 years as the advanced bladder chair for SWOG, Dr. Petrylak is now the Vice Chair of the Genitourinary Committee.
